In RAS wild-type metastatic CRC patients receiving anti-EGFR monoclonal antibody cetuximab and fluoropyrimidine-based therapy, upregulation of miR-31-5p and miR-31-3p correlated with worse progression-free survival. The gene discussed is EGFR; the disease is colorectal carcinoma.